The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Immunic Inc shares valued at $16,694 were purchased by Nash Duane on Jun 13 ’25. At $0.83 per share, Nash Duane acquired 20,000 shares. The insider’s holdings grew to 36,032 shares worth approximately $27024.0 following the completion of this transaction.
Also, Tardio Jason purchased 12,512 shares, netting a total of over 9,884 in proceeds. Following the buying of shares at $0.79 each, the insider now holds 12,512 shares.
Before that, Vitt Daniel had added 15,000 shares to its account. In a trade valued at $11,550, the CEO and Director bought Immunic Inc shares for $0.77 each. Upon closing the transaction, the insider’s holdings increased to 15,000 shares, worth approximately $21750.0.
As published in their initiating research note from William Blair on March 25, 2025, Immunic Inc [IMUX] has been an Outperform. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late November. Earlier on August 27, 2024, B. Riley Securities initiated its rating. Their recommendation was “a Buy” for IMUX stock.
Analyzing IMUX Stock Performance
On last trading session,, Immunic Inc [NASDAQ: IMUX] plunged -2.75% to $0.75. During the last five days, there has been a drop of approximately -14.21%. Over the course of the year, Immunic Inc shares have dropped approximately -25.36%. Shares of the company reached a 52-week high of $1.3900 on 02/21/25 and a 52-week low of $0.5600 on 05/29/25.
Support And Resistance Levels for Immunic Inc (IMUX)
According to the 24-hour chart, there is a support level at 0.6978, which, if violated, would cause prices to drop to 0.6492. In the upper region, resistance lies at 0.8050. The next price resistance is at 0.8636. RSI (Relative Strength Index) is 38.47 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Immunic Inc (IMUX)?
In terms of Immunic Inc share price expectations, FactSet research, analysts set an average price target of 5 in the next 12 months, up nearly 549.35% from the previous closing price of $0.77. Analysts anticipate Immunic Inc stock to reach 5 by 2025, with the lowest price target being 5. In spite of this, 3 analysts ranked Immunic Inc stock as Buy at the end of 2025. On October 21, 2022, SVB Leerink assigned a price target of “a Mkt perform” to the stock and downgraded coverage with a $5.
